HiFiBiO Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 69
Employees
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $75M
Latest Deal Amount
  • Investors
  • 19

HiFiBiO Therapeutics General Information

Description

Developer of a single-cell analytics platform designed to mobilize the human immune system to combat cancer and autoimmune disorders. The company's platform integrate deep-rooted biological expertise with their comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody, enabling doctors to unlock the curative powers of the immune system with innovative biotherapeutics.

Contact Information

Website
www.hifibio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 237 Putnam Avenue
  • Cambridge, MA 02139
  • United States

HiFiBiO Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HiFiBiO Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 14-Jun-2021 $75M 00000 Completed Generating Revenue
5. Debt - PPP 27-Apr-2020 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 28-Aug-2019 0000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 16-May-2018 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 27-Jan-2017 $4.21M $4.21M 000.00 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view HiFiBiO Therapeutics’s complete valuation and funding history, request access »

HiFiBiO Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
P 000,000 00.000000 00.00 00.00 00 00.00 00.000
P 000,000 00.000000 00.00 00.00 00 00.00 0.000
P 195,089 $0.010609 $10.31 $10.31 1x $10.31 12.87%
Ordinary 1,000,000 $0.010609
To view HiFiBiO Therapeutics’s complete cap table history, request access »

HiFiBiO Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a single-cell analytics platform designed to mobilize the human immune system to combat cancer and autoimmu
Drug Discovery
Cambridge, MA
69 As of 2021
00000
00000000000 00000

00000000

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
San Carlos, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000 0

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HiFiBiO Therapeutics Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexigen Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
00000000 000000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
000000000 Formerly VC-backed Vancouver, Canada 000 00000 00000000 00000
You’re viewing 5 of 57 competitors. Get the full list »

HiFiBiO Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Liang Schweizer Ph.D Co-Founder, Chief Scientific Officer, Chief Executive Officer & President
Philip Sin Chief Financial Officer
Jeff He Co-Founder & Chief Operating Officer
Andrew Griffiths Ph.D Scientific Co-Founder
Jerome Bibette Ph.D Scientific Co-Founder
You’re viewing 5 of 13 executive team members. Get the full list »

HiFiBiO Therapeutics Board Members (2)

Name Representing Role Since
Ryan Jeong Mirae Asset Global Investments Board Member 000 0000
Tiger Hu MD IDG Capital Board Member 000 0000
To view HiFiBiO Therapeutics’s complete board members history, request access »

HiFiBiO Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HiFiBiO Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
B Capital Group Venture Capital Minority 000 0000 000000 0
Grand Mount Capital Venture Capital Minority 000 0000 000000 0
Hengxu Other Minority 000 0000 000000 0
HKSTP Ventures Corporate Venture Capital Minority 000 0000 000000 0
Maison Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

HiFiBiO Therapeutics Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 10-Dec-2018 00000 0000000 Biotechnology 00000 000000000 00.0
H-Immune Therapeutics 15-Oct-2018 Merger/Acquisition Drug Discovery 00000 000000000 00.0
To view HiFiBiO Therapeutics’s complete investments and acquisitions history, request access »